SCLX
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Scilex Holding Company (SCLX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Momentum (D-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B (3.4) | D (1.3) | C+ (2.5) | D- (0.9) | C+ (2.6) | C (2.2) |
| 2026-11-07 | B (3.4) | D (1.3) | C+ (2.6) | D- (0.8) | C+ (2.7) | C- (2.1) |
| 2026-10-31 | B (3.4) | D (1.2) | C+ (2.6) | D- (0.9) | C+ (2.7) | C (2.2) |
| 2026-10-24 | B (3.4) | D (1.2) | C+ (2.6) | D+ (1.7) | C+ (2.6) | C (2.3) |
| 2026-10-17 | B (3.3) | D (1.2) | C+ (2.6) | D+ (1.8) | C+ (2.6) | C (2.3) |